Lotus Pharmaceuticals Inc. Stock Analysis LTUS
United States Health Care Nano Cap Lotus Pharmaceuticals, Inc. engages in the manufacture and distribution of pharmaceutical products in the People's Republic of China. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2012-05-15. The firm produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The firm's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The firm operated in two business segment Wholesales segment and Retail segment. The firm's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The firm mainly conducts its businesses in the domestic market and overseas markets.
Read More Lotus Pharmaceuticals Inc (LTUS) Chart
Key Statistics of Lotus Pharmaceuticals Inc (LTUS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
2900.00P/E Ratio (TTM)
0.6652 Week Range
Market Cap
100.14KAvg. Volume
2900.00Dividend Yield
-Financial Metrics & Statements of Lotus Pharmaceuticals Inc (LTUS)
FAQ's for Lotus Pharmaceuticals Inc (LTUS)
- According to Musaffa’s Shariah screening methodology, Lotus Pharmaceuticals Inc (LTUS) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.